DAVID A LOWE
Electrician in Boston, MA

License number
Massachusetts 16957
Issued Date
Apr 24, 2000
Expiration Date
Jul 31, 2019
Type
Master Electrician
Address
Address
Boston, MA 02118

Personal information

See more information about DAVID A LOWE at radaris.com
Name
Address
Phone
David Lowe
4 Kingswood Dr APT B2, Abington, MA 02351
David Lowe
42 Tavern Cir, Sudbury, MA 01776
David Lowe
51 Exchange St, Milford, MA 01757

Organization information

See more information about DAVID A LOWE at bizstanding.com

Boston Children's Hospital - David Lowe MD

300 Longwood Ave #FEGAN10, Boston, MA 02115

Categories:
Physicians & Surgeons
Phone:
(617) 355-6000 (Phone)
Products:
Cardiology


David Lowe BS,MBBS,MD

300 Longwood Ave, Boston, MA 02115

Industry:
Pediatrician
Phone:
(617) 355-6624 (Phone)
David Alexander Lowe

Professional information

David Lowe Photo 1

Author (In Progress); Past Program Director; International And Local Community Conservation And Engagement Leader

Position:
Author (in progress): Energy Primer at Lowe Energy Education, Board Member; former Chair at Climate Action Brookline (CAB; formerly CCAB), Town Meeting Member at Brookline Town community, Board Member at Massachusetts Climate Action Network (MCAN), Founding Member at Landcare International Steering Committee
Location:
Greater Boston Area
Industry:
Renewables & Environment
Work:
Lowe Energy Education - Brookline, MA since May 2011 - Author (in progress): Energy Primer Climate Action Brookline (CAB; formerly CCAB) - Brookline, MA since 2011 - Board Member; former Chair Brookline Town community - Brookline, MA since 2010 - Town Meeting Member Massachusetts Climate Action Network (MCAN) - 70 communities across the Commonwealth of Massachusetts since 2007 - Board Member Landcare International Steering Committee - Nairobi-based network that spans five continents since 2004 - Founding Member Energy Points Inc. 2011 - 2012 - Early collaborator; Education Sector Outreach Climate Change Action Brookline - Brookline, MA 2007 - 2010 - Former Chair & Co-Chair Landcare International 2004 - 2010 - Steering Committee Member Climate Change Action Brookline 2007 - 2009 - Leader EcoLogic Development Fund 2004 - 2006 - Consultant - program & proposal development Earthwatch Institute 1996 - 2004 - Program Director for Life Sciences Boston Area Returned Peace Corps Association 1997 - 2002 - Board Member Stony Brook University/Institute for Conservation of Tropical Environments 1995 - 1996 - Program Officer US Congress, Office of Technology Assessment 1993 - 1995 - Contractor, Researcher & Writer, Study contributor USAID 1992 - 1993 - Contractor, Energy and Infrastructure National Museums of Kenya 1989 - 1991 - Research Associate; Program Director US Peace Corps 1984 - 1985 - Campus Recruiter, Cornell University Peace Corps/Kenya 1978 - 1981 - Volunteer
Education:
Cornell University 1983 - 1986
Masters, International Agriculture and Rural Development
State University of New York at Stony Brook 1973 - 1977
BS, Earth and Space Sciences
JFK HS
Skills:
Energy Efficiency, Sustainability, Environmental Policy, Sustainable Development, Non-profits, Environmental Awareness, Renewable Energy, Environmental Education, Energy, Climate Change, Community Development, Green, Government Administration, Public Policy, Grant Writing, International Development, Fundraising, Program Development, Grants, Policy Analysis, Research, Strategy, Proposal Writing, Science, Conservation Issues, Nonprofits, Community Engagement, Leadership


David Lowe Photo 2

Transgenic Flies Expressing Abeta42-Arctic

US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/969893
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000
Abstract:
The present invention discloses a transgenic fly that expresses the Arctic mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.


David Lowe Photo 3

Transgenic Flies Expressing Abeta42-Flemish

US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/969895
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000, 800013000
Abstract:
The present invention discloses a transgenic fly that expresses the Flemish mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.


David Lowe Photo 4

Transgenic Flies Expressing Abeta42-Iowa

US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/969894
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000, 800013000
Abstract:
The present invention discloses a transgenic fly that expresses the Iowa mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.


David Lowe Photo 5

Transgenic Flies Expressing Abeta42-Dutch

US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/969898
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000, 800013000
Abstract:
The present invention discloses a transgenic fly that expresses the Dutch mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.


David Lowe Photo 6

Transgenic Flies Expressing Abeta42-Flemish

US Patent:
2004024, Dec 2, 2004
Filed:
May 25, 2004
Appl. No.:
10/852892
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Assignee:
EnVivo Pharmaceuticals, Inc.
International Classification:
A01K067/033
US Classification:
800/003000, 800/008000
Abstract:
The present invention discloses a transgenic fly that expresses the Flemish mutant version of the human A42 peptide of human amyloid- precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A42peptide of human amyloid- precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.


David Lowe Photo 7

Transgenic Flies Expressing Abeta42-Italian

US Patent:
2005013, Jun 16, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/970189
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
International Classification:
A01K067/033
US Classification:
800008000, 800009000, 800013000
Abstract:
The present invention discloses a transgenic fly that expresses the Italian mutant version of the human Aβ42 peptide of human amyloid-β precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human Aβ42peptide of human amyloid-β precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.


David Lowe Photo 8

Transgenic Flies Expressing Abeta42-Dutch

US Patent:
2004025, Dec 9, 2004
Filed:
May 25, 2004
Appl. No.:
10/853593
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Assignee:
EnVivo Pharmaceuticals, Inc.
International Classification:
A01K067/033
US Classification:
800/008000, 800/009000
Abstract:
The present invention discloses a transgenic fly that expresses the Dutch mutant version of the human A42 peptide of human amyloid- precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A42peptide of human amyloid- precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.


David Lowe Photo 9

Transgenic Flies Expressing Abeta42-Arctic

US Patent:
2004025, Dec 16, 2004
Filed:
May 25, 2004
Appl. No.:
10/852951
Inventors:
David Lowe - Boston MA, US
Gerhard Koenig - Arlington MA, US
Christopher Cummings - Brookline MA, US
Assignee:
EnVivo Pharmaceuticals, Inc.
International Classification:
G01N033/00, A01K067/00, A01K067/033
US Classification:
800/003000, 800/013000
Abstract:
The present invention discloses a transgenic fly that expresses the Arctic mutant version of the human A42 peptide of human amyloid- precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A42peptide of human amyloid- precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.


David Lowe Photo 10

David Lowe

Location:
Greater Boston Area
Industry:
Pharmaceuticals